No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Identifieur interne : 001A36 ( Main/Corpus ); précédent : 001A35; suivant : 001A37No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
Auteurs : J M Molina ; C. Delaugerre ; J. Le Goff ; B. Mela-Lima ; D. Ponscarme ; L. Goldwirt ; N. De CastroSource :
- Medecine et maladies infectieuses [ 1769-6690 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (isolation & purification), COVID-19 (MeSH), Coronavirus Infections (therapy), Drug Therapy, Combination (standards), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (therapy), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Antiviral Agents, Azithromycin, Hydroxychloroquine.
- isolation & purification : Betacoronavirus.
- standards : Drug Therapy, Combination.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, COVID-19, Female, Humans, Male, Middle Aged, Pandemics, SARS-CoV-2, Treatment Outcome, Young Adult.
DOI: 10.1016/j.medmal.2020.03.006
PubMed: 32240719
PubMed Central: PMC7195369
Links to Exploration step
pubmed:32240719Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.</title><author><name sortKey="Molina, J M" sort="Molina, J M" uniqKey="Molina J" first="J M" last="Molina">J M Molina</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Delaugerre, C" sort="Delaugerre, C" uniqKey="Delaugerre C" first="C" last="Delaugerre">C. Delaugerre</name><affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Goff, J" sort="Le Goff, J" uniqKey="Le Goff J" first="J" last="Le Goff">J. Le Goff</name><affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mela Lima, B" sort="Mela Lima, B" uniqKey="Mela Lima B" first="B" last="Mela-Lima">B. Mela-Lima</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ponscarme, D" sort="Ponscarme, D" uniqKey="Ponscarme D" first="D" last="Ponscarme">D. Ponscarme</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Goldwirt, L" sort="Goldwirt, L" uniqKey="Goldwirt L" first="L" last="Goldwirt">L. Goldwirt</name><affiliation><nlm:affiliation>Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="De Castro, N" sort="De Castro, N" uniqKey="De Castro N" first="N" last="De Castro">N. De Castro</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32240719</idno><idno type="pmid">32240719</idno><idno type="doi">10.1016/j.medmal.2020.03.006</idno><idno type="pmc">PMC7195369</idno><idno type="wicri:Area/Main/Corpus">001A36</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.</title><author><name sortKey="Molina, J M" sort="Molina, J M" uniqKey="Molina J" first="J M" last="Molina">J M Molina</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Delaugerre, C" sort="Delaugerre, C" uniqKey="Delaugerre C" first="C" last="Delaugerre">C. Delaugerre</name><affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Goff, J" sort="Le Goff, J" uniqKey="Le Goff J" first="J" last="Le Goff">J. Le Goff</name><affiliation><nlm:affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mela Lima, B" sort="Mela Lima, B" uniqKey="Mela Lima B" first="B" last="Mela-Lima">B. Mela-Lima</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Ponscarme, D" sort="Ponscarme, D" uniqKey="Ponscarme D" first="D" last="Ponscarme">D. Ponscarme</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Goldwirt, L" sort="Goldwirt, L" uniqKey="Goldwirt L" first="L" last="Goldwirt">L. Goldwirt</name><affiliation><nlm:affiliation>Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="De Castro, N" sort="De Castro, N" uniqKey="De Castro N" first="N" last="De Castro">N. De Castro</name><affiliation><nlm:affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Medecine et maladies infectieuses</title><idno type="eISSN">1769-6690</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Antiviral Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (isolation & purification)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (therapy)</term><term>Drug Therapy, Combination (standards)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (therapy)</term><term>SARS-CoV-2 (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>COVID-19</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>SARS-CoV-2</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32240719</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6690</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Medecine et maladies infectieuses</Title><ISOAbbreviation>Med Mal Infect</ISOAbbreviation></Journal><ArticleTitle>No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.</ArticleTitle><Pagination><MedlinePgn>384</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0399-077X(20)30085-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medmal.2020.03.006</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delaugerre</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Goff</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mela-Lima</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponscarme</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldwirt</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Castro</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Med Mal Infect</MedlineTA><NlmUniqueID>0311416</NlmUniqueID><ISSNLinking>0399-077X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId><ArticleId IdType="pii">S0399-077X(20)30085-8</ArticleId><ArticleId IdType="doi">10.1016/j.medmal.2020.03.006</ArticleId><ArticleId IdType="pmc">PMC7195369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2012 Jul 25;308(4):353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22820788</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785</Citation><ArticleIdList><ArticleId IdType="pubmed">20706626</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2018 May 17;10(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation><ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001A36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32240719
|texte= No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32240719" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |